CTMX

CytomX Therapeutics Inc.

Price

$3.57

return (12m)

78.50%

p/e

-9.14

p/bv

2.41

DIVIDEND YIELD

0.00%

CTMX price

CytomX Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment CTMX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

4.69%

3 months

-5.05%

1 year

78.50%

2 years

190.24%

5 years

-23.39%

10 years

-67.95%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals CTMX

Valuation

P/E

-9.14

Sector -4.38

Industry -4.38

P/BV

2.41

Sector 2.02

Industry 2.02

P/Revenue (PSR)

39.79

Sector -4.40

Industry -4.40

EV/EBITDA

-16.77

Sector -263.09

Industry -263.09

EV/EBIT

-16.73

Sector -702.90

Industry -702.90

P/EBITDA

-8.45

Sector -4.39

Industry -4.39

P/EBIT

-8.36

Sector -4.73

Industry -4.73

P/Total Assets

1.91

Sector 1.49

Industry 1.49

P/Net Current Assets

2.48

Sector -11.70

Industry -11.70

P/Working Capital

2.18

Sector -3.19

Industry -3.19

EPS

-0.36

Sector -2.14

Industry -2.14

BVPS

1.38

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-1,671.13%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-1,674.65%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-26.37%

Sector -65.14%

Industry -65.14%

ROA

-20.90%

Sector -65.53%

Industry -65.53%

ROIC

-298.91%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

9.36

Sector 2.90

Industry 2.90

Net Debt / EBITDA

13.92

Sector -6.07

Industry -6.07

Net Debt / EBIT

13.89

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.09

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.79

Sector 0.41

Industry 0.41

Liabilities/Assets

0.21

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-13.28%

Sector -

Industry -

5Y Earnings CAGR

-7.22%

Sector -

Industry -

Fundamentals CTMX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
CTMX CytomX Therapeutics Inc.	$3.57	68.40%	0.00%	-9.14	2.41	-26.37%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

CTMX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT CytomX Therapeutics

CytomX Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

16 years

Founded: 2010

2015

Time since IPO - 11 years

160

Employees

CytomX Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $728.18 million, with shareholders equity totaling $302.07 million.

The company employs approximately 160 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, CytomX Therapeutics Inc. reported $18.30 million in revenue, generating net income of $-79.66 million.

Key financial metrics include a P/E ratio of -9.14, a price-to-book (P/B) ratio of 2.41, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker CTMX.

Market cap

$728.18 million

Net worth

$302.07 million

$302,070,000.00

Assets

$381.23 million

$381,230,000.00

Total Shares Outstanding

219.00 million

219,000,000

Average Daily Trading Volume

$4.10 million

$4,095,268.80

Sector

Health Care

Industry

Biotechnology

CTMX

CTMX revenue and profits

Financial Results CTMX

DRAG THE FRAME TO SEE MORE DATA

CTMX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of CytomX Therapeutics (CTMX) today?

A cotação de CytomX Therapeutics (CTMX) hoje está em US$ 3.57, com uma variação de 78.5% em relação ao último ano. A cotação de CytomX Therapeutics (CTMX) iniciou o ano negociando na casa dos US$ 4.26 e hoje está em US$ 3.57. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de CytomX Therapeutics (CTMX) e dados de ações do Ibovespa e mercados internacionais.

Quando CytomX Therapeutics (CTMX) paga dividendos?

CytomX Therapeutics (CTMX) não distribuiu dividendos no último ano.

Is CytomX Therapeutics (CTMX) a good investment?

Atualmente, CytomX Therapeutics (CTMX) está cotada a US$ 3.57, com um P/L de -9.14, representando um desvio de -5,422% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 78.5 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 78.50%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy CytomX Therapeutics (CTMX) stock?

Investir em ações de CytomX Therapeutics (CTMX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of CytomX Therapeutics (CTMX) yield today?

A rentabilidade de CytomX Therapeutics (CTMX) foi de 4.69% no último mês, 78.50% no último ano e -23.39% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de CytomX Therapeutics (CTMX) hoje, o investimento total seria de US$ 357.00, com base na cotação atual de US$ 3.57.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 637.25
Em 5 anos: US$ 273.50
Em 10 anos: US$ 114.42

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CTMX

CytomX Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CTMX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING CTMX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT CytomX Therapeutics

CytomX Therapeutics Inc.

United States

16 years

2015

160

PROFIT X PRICE CTMX

Financial Results CTMX

CTMX cash flow

Asset, Revenue and Profit Growth - CTMX

CTMX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions